MA39837B1 - Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 - Google Patents

Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1

Info

Publication number
MA39837B1
MA39837B1 MA39837A MA39837A MA39837B1 MA 39837 B1 MA39837 B1 MA 39837B1 MA 39837 A MA39837 A MA 39837A MA 39837 A MA39837 A MA 39837A MA 39837 B1 MA39837 B1 MA 39837B1
Authority
MA
Morocco
Prior art keywords
thf
amines
pde1 inhibitors
quinazolin
halogenated
Prior art date
Application number
MA39837A
Other languages
English (en)
Inventor
Lars Kyhn Rasmussen
Morten Langgård
Jan Kehler
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA39837B1 publication Critical patent/MA39837B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

La présente invention concerne des quinazoline-thf-amines halogénées utilisées en tant qu'inhibiteurs de la pde1 ainsi que leur utilisation en tant que médicament, en particulier pour le traitement de troubles neurodégénératifs et de troubles psychiatriques.
MA39837A 2014-04-04 2015-03-27 Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 MA39837B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400194 2014-04-04
PCT/EP2015/056713 WO2015150254A1 (fr) 2014-04-04 2015-03-27 Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1

Publications (1)

Publication Number Publication Date
MA39837B1 true MA39837B1 (fr) 2020-05-29

Family

ID=52779655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39837A MA39837B1 (fr) 2014-04-04 2015-03-27 Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1

Country Status (38)

Country Link
US (2) US10005764B2 (fr)
EP (1) EP3126354B1 (fr)
JP (1) JP6554116B2 (fr)
KR (1) KR20160138084A (fr)
CN (2) CN106132953B (fr)
AP (1) AP2016009521A0 (fr)
AR (1) AR101155A1 (fr)
AU (1) AU2015239696B2 (fr)
CA (1) CA2943011A1 (fr)
CL (1) CL2016002515A1 (fr)
CR (1) CR20160463A (fr)
CY (1) CY1122784T1 (fr)
DK (1) DK3126354T3 (fr)
DO (1) DOP2016000263A (fr)
EA (1) EA032579B1 (fr)
EC (1) ECSP16082599A (fr)
ES (1) ES2776359T3 (fr)
GE (1) GEP20186920B (fr)
GT (1) GT201600213A (fr)
HR (1) HRP20200369T1 (fr)
IL (1) IL248078B (fr)
JO (1) JO3628B1 (fr)
LT (1) LT3126354T (fr)
MA (1) MA39837B1 (fr)
MX (1) MX364519B (fr)
PE (1) PE20161380A1 (fr)
PH (1) PH12016501938A1 (fr)
PL (1) PL3126354T3 (fr)
PT (1) PT3126354T (fr)
RS (1) RS60017B1 (fr)
RU (1) RU2692808C2 (fr)
SG (1) SG11201608190YA (fr)
SI (1) SI3126354T1 (fr)
SV (1) SV2016005297A (fr)
TW (1) TWI664178B (fr)
UA (1) UA119166C2 (fr)
WO (1) WO2015150254A1 (fr)
ZA (1) ZA201606566B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3126354T (lt) 2014-04-04 2020-03-25 H. Lundbeck A/S Halogeninti kvinazolin-thf-aminai kaip pde1 inhibitoriai
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
MX2020005447A (es) * 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
ZA200507979B (en) * 2003-03-03 2007-03-28 Vertex Pharma Inc Quinazolines useful as modulators of ion channels
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
WO2007096743A1 (fr) * 2006-02-23 2007-08-30 Pfizer Products Inc. Quinazolines substituées en tant qu'inhibiteurs de pde10
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
JP2013505909A (ja) * 2009-09-24 2013-02-21 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物害虫を駆除するためのアミノキナゾリン化合物
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201609713A (zh) * 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
TW201611834A (en) * 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
SG11201608108SA (en) 2014-04-04 2016-10-28 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
MA52856B1 (fr) 2014-04-04 2022-03-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
LT3126354T (lt) 2014-04-04 2020-03-25 H. Lundbeck A/S Halogeninti kvinazolin-thf-aminai kaip pde1 inhibitoriai
TW201623286A (zh) 2014-04-04 2016-07-01 賽諾菲公司 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物
EA030032B1 (ru) 2014-04-04 2018-06-29 Ф. Хоффманн-Ля Рош Аг 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類

Also Published As

Publication number Publication date
PT3126354T (pt) 2020-03-17
PH12016501938A1 (en) 2017-02-06
AP2016009521A0 (en) 2016-10-31
JO3628B1 (ar) 2020-08-27
MX2016012955A (es) 2016-12-07
US20170022186A1 (en) 2017-01-26
TW201620901A (zh) 2016-06-16
TWI664178B (zh) 2019-07-01
KR20160138084A (ko) 2016-12-02
PL3126354T3 (pl) 2020-06-15
DK3126354T3 (da) 2020-03-09
SG11201608190YA (en) 2016-10-28
RU2016138743A (ru) 2018-05-07
CN106132953A (zh) 2016-11-16
PE20161380A1 (es) 2017-01-15
GT201600213A (es) 2019-07-29
DOP2016000263A (es) 2016-11-30
RS60017B1 (sr) 2020-04-30
LT3126354T (lt) 2020-03-25
EA032579B1 (ru) 2019-06-28
CL2016002515A1 (es) 2016-12-16
US20190144434A1 (en) 2019-05-16
WO2015150254A1 (fr) 2015-10-08
GEP20186920B (en) 2018-11-12
EA201691773A1 (ru) 2017-01-30
ES2776359T3 (es) 2020-07-30
EP3126354A1 (fr) 2017-02-08
AR101155A1 (es) 2016-11-30
JP6554116B2 (ja) 2019-07-31
ZA201606566B (en) 2017-11-29
US10005764B2 (en) 2018-06-26
CN106132953B (zh) 2019-03-22
CY1122784T1 (el) 2021-05-05
SV2016005297A (es) 2016-11-30
RU2692808C2 (ru) 2019-06-27
ECSP16082599A (es) 2017-02-24
IL248078B (en) 2018-11-29
RU2016138743A3 (fr) 2019-01-15
CR20160463A (es) 2017-03-06
AU2015239696B2 (en) 2019-10-24
SI3126354T1 (sl) 2020-04-30
MX364519B (es) 2019-04-30
HRP20200369T1 (hr) 2020-08-07
CA2943011A1 (fr) 2015-10-08
CN109999039A (zh) 2019-07-12
JP2017509680A (ja) 2017-04-06
US10526319B2 (en) 2020-01-07
EP3126354B1 (fr) 2020-01-22
AU2015239696A1 (en) 2016-10-06
UA119166C2 (uk) 2019-05-10

Similar Documents

Publication Publication Date Title
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA41013A (fr) Compositions comprenant des souches bactériennes
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MA38814A1 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
MA44656B1 (fr) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA39230B1 (fr) Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1
MX2017006692A (es) Trastornos neurodegenerativos.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MA39118B1 (fr) Quinazoline-thf-amines utilisées en tant qu'inhibiteurs de la pde1
FR3057455B1 (fr) Equipement pour le traitement d'une fracture par haubanage, par exemple d'une fracture de l'olecrane ou de la rotule
MA45537B1 (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MA40065B1 (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
MA41104A (fr) Compositions comprenant des souches bactériennes
MA41059A (fr) Compositions comprenant des souches bactériennes